Company news
Dermata Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
January 3, 2024
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 19, 2023
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
November 15, 2023
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
November 15, 2023
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 8, 2023
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 9, 2023
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
June 26, 2023
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9: 00 A.M. ET
June 12, 2023
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
June 7, 2023
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 25, 2023
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 23, 2023
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
April 19, 2023
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 19, 2023
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
March 15, 2023
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
February 20, 2023
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
December 4, 2022
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 9, 2022
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 23, 2022
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 14, 2022
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
June 12, 2022
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 22, 2022
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 15, 2022
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 24, 2022
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 20, 2022
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 27, 2022
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
March 23, 2022
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
January 12, 2022
Dermata to Present at the H.C. Wainwright BioConnect Conference
January 4, 2022
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 18, 2021
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 16, 2021
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 11, 2021
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 17, 2021
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 26, 2021
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
August 31, 2021
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
August 16, 2021
Decks
- IPO Roadshow (July 2021)
IPO roadshow · 31 slides · Jul 12, 2021